FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.4-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

373692009: Substance with phosphodiesterase inhibitor mechanism of action (substance)

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2018. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
1212151018 Phosphodiesterase inhibitor en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3520795018 Substance with phosphodiesterase inhibitor mechanism of action (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3520964015 Substance with phosphodiesterase inhibitor mechanism of action en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
1198992010 Phosphodiesterase inhibitor (substance) en Fully specified name Active Only initial character case insensitive (core metadata concept) SNOMED CT core
1198992010 Phosphodiesterase inhibitor (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
1212151018 Phosphodiesterase inhibitor en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core
1212151018 Phosphodiesterase inhibitor en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3520795018 Substance with phosphodiesterase inhibitor mechanism of action (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3520964015 Substance with phosphodiesterase inhibitor mechanism of action en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
188931000077117 inhibiteur de la phosphodiestérase fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
188931000077117 inhibiteur de la phosphodiestérase fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

39 descendants. Search Descendants:

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Phosphodiesterase inhibitor Is a Inotropic agent (substance) false Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase inhibitor Is a Enzyme inhibitor false Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase inhibitor Is a Substance with hydrolase inhibitor mechanism of action (substance) true Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase inhibitor Has disposition Phosphodiesterase inhibitor (disposition) true Inferred relationship Existential restriction modifier (core metadata concept)
Inbound Relationships Type Active Source Characteristic Refinability Group
Milrinone (substance) Is a False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase inhibitor poisoning (disorder) Causative agent (attribute) True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Accidental phosphodiesterase inhibitor poisoning Causative agent (attribute) False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Intentional phosphodiesterase inhibitor poisoning Causative agent (attribute) False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase inhibitor poisoning of undetermined intent Causative agent (attribute) False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 2
Phosphodiesterase inhibitor adverse reaction Causative agent (attribute) True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Allergy to phosphodiesterase inhibitor (finding) Causative agent (attribute) False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase inhibitor overdose Causative agent (attribute) True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Accidental phosphodiesterase inhibitor overdose (disorder) Causative agent (attribute) True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Intentional phosphodiesterase inhibitor overdose (disorder) Causative agent (attribute) True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Phosphodiesterase inhibitor overdose of undetermined intent Causative agent (attribute) False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Product containing phosphodiesterase inhibitor (product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept) 1
Enoximone Is a False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Cilostazol Is a False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Phosphodiesterase 5 inhibitor Is a True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Theophylline (substance) Is a True Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Amrinone Is a False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 100mg tablet (substance) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
aminophylline 25 mg/mL, ampoule de 10 mL de solution pour injection The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 225mg modified release tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 350mg m/r tablet (substance) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 100mg modified release tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
aminophylline 25 mg/mL, seringue préremplie de 10 mL de solution pour injection The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine solution The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Ergotamine tartrate+caffeine 2mg/100mg suppository (substance) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing xanthine (product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Oral aminophylline The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine 5mg/mL injection solution 2mL vial The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine and sodium benzoate injection solution vial The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aminophylline (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing caffeine (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing caffeine and dihydrocodeine tartrate and paracetamol The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Xanthine bronchodilators The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin- and caffeine- and cinnamedrine-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aspirin and caffeine and orphenadrine (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing caffeine and paracetamol and salicylamide (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing buffered aspirin and caffeine (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin- and caffeine- and paracetamol-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aspirin and caffeine (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline 250mg/2cc The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline 160mg/15ml elixir The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline 100mg/15mL The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline 200mg (product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely diprophylline 400 milligram/1 each conventional release oral tablet (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine citrate 20mg/mL injection (product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine citrate 20mg solution The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Acetaminophen+butalbital+caffeine 325mg/50mg/40mg capsule The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Acetaminophen+butalbital+caffeine 500mg/50mg/40mg tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin + butalbital + caffeine 325mg/50mg/40mg tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely aspirin 770 milligram and caffeine 60 milligram and orphenadrine citrate 50 milligram/1 each conventional release oral tablet (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline + guaifenesin 100mg/100mg elixir The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline + guaifenesin 100mg/100mg liquid The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline + guaifenesin 100mg/100mg syrup The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely diprophylline 100 milligram and guaifenesin 100 milligram/1 each conventional release oral tablet (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline + guaifenesin 100mg/50mg syrup The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline + guaifenesin 200mg/100mg capsule The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Diprophylline 200 mg and guaifenesin 200 mg oral tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 25mg/mL injection solution 10mL vial The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 25mg/mL injection solution 10mL amp The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 250mg/10mL injection The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing diprophylline (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin + caffeine + orphenadrine citrate tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Oral caffeine (product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing caffeine in rectal dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing caffeine in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline m/r tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline-containing product in rectal dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 250 mg rectal suppository The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely aminophylline 500 milligram/1 each conventional release rectal suppository (clinical drug) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 200 mg oral tablet The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aminophylline 105mg/5ml oral liquid The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing diprophylline in oral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Parenteral dyphylline The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Dyphylline+guaifenesin 100mg/100mg liquid The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aspirin and butalbital and caffeine and codeine phosphate The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing caffeine and isometheptene mucate and paracetamol The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Diprophylline- and guaifenesin-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aspirin and caffeine and propoxyphene hydrochloride The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aspirin and caffeine and dihydrocodeine tartrate The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine + ergotamine tartrate The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Caffeine- and sodium benzoate-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing butalbital and caffeine and paracetamol (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Aspirin + caffeine + orphenadrine citrate The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing butalbital and caffeine and codeine phosphate and paracetamol The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)
Product containing aspirin and butalbital and caffeine (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Phosphodiesterase inhibitor Inferred relationship Existential restriction modifier (core metadata concept)

Page 1 of 2 End

This concept is not in any reference sets

Back to Start